1Ismail Ibrahim Ismail, 1,2Jasem Al-Hashel, 3Raed Alroughani, 1,4Samar Farouk Ahmed
1Ibn Sina Hospital, Kuwait city, Kuwait; 2Health Sciences Centre, Kuwait University, Jabriya, Kuwait; 3Amiri Hospital, Sharq, Kuwait; 4Minia University, Minia, Egypt
Since the declaration of COVID-19 pandemic, several cases of demyelination of both peripheral and central nervous systems have been reported. The association of viral infection and the development of CNS demyelination has long been studied, and this link has recently been reported following SARS-CoV-2 infection as well.
Material(s) and Method(s):
We report a case of a 36-year-old male who developed CNS demyelinating disease, that fulfilled the diagnostic criteria of multiple sclerosis (MS), 2 months after laboratory-confirmed infection with SARS-CoV-2.
A 36-year-old male developed CNS demyelination, 2-months following a laboratory-confirmed SARS-CoV-2 infection, that fulfilled the revised 2017 McDonald diagnostic criteria for MS. He presented with ataxia, and MRI showed multiple demyelinating lesions in the brain, and positive oligoclonal bands in CSF.
To our knowledge, this is the second case report of MS in association with COVID-19 infection, and the first case from Middle East and North Africa (MENA) region. This case report adds to the growing body of evidence of a probable causal relationship between SARS‐CoV‐2 infection and the development of MS. SARS-CoV-2 could potentially trigger a demyelinating process, through an acute or delayed immune-mediated CNS inflammatory response.